The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
The global Cystic Fibrosis Therapeutics market was valued at US$ 5060.5 million in 2023 and is anticipated to reach US$ 12680 million by 2030, witnessing a CAGR of 13.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Cystic Fibrosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cystic Fibrosis Therapeutics.
Report Scope
The Cystic Fibrosis Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cystic Fibrosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cystic Fibrosis Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
- Vertex Pharmaceuticals
- F. Hoffmann-La Roche
- AbbVie
- Gilead Sciences
- Novartis
- AstraZeneca
- Bayer
- Celtaxsys
- Pharmaxis
- ProQR Therapeutics
- PTC Therapeutics
- Alcresta Therapeutics
- Insmed Incorporated
- Savara
- Cyclacel Pharmaceuticals
- Vectura
- Allergan
By Type
- CFTR
- Mucolytics
- PERT
- Anti-infectives
- Bronchodilators
By Application
- Hospitals
- Clinics
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cystic Fibrosis Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cystic Fibrosis Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CFTR
1.2.3 Mucolytics
1.2.4 PERT
1.2.5 Anti-infectives
1.2.6 Bronchodilators
1.3 Market by Application
1.3.1 Global Cystic Fibrosis Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cystic Fibrosis Therapeutics Market Perspective (2019-2030)
2.2 Cystic Fibrosis Therapeutics Growth Trends by Region
2.2.1 Global Cystic Fibrosis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Cystic Fibrosis Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Cystic Fibrosis Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Cystic Fibrosis Therapeutics Market Dynamics
2.3.1 Cystic Fibrosis Therapeutics Industry Trends
2.3.2 Cystic Fibrosis Therapeutics Market Drivers
2.3.3 Cystic Fibrosis Therapeutics Market Challenges
2.3.4 Cystic Fibrosis Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cystic Fibrosis Therapeutics Players by Revenue
3.1.1 Global Top Cystic Fibrosis Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Cystic Fibrosis Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Cystic Fibrosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cystic Fibrosis Therapeutics Revenue
3.4 Global Cystic Fibrosis Therapeutics Market Concentration Ratio
3.4.1 Global Cystic Fibrosis Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cystic Fibrosis Therapeutics Revenue in 2023
3.5 Cystic Fibrosis Therapeutics Key Players Head office and Area Served
3.6 Key Players Cystic Fibrosis Therapeutics Product Solution and Service
3.7 Date of Enter into Cystic Fibrosis Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cystic Fibrosis Therapeutics Breakdown Data by Type
4.1 Global Cystic Fibrosis Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Cystic Fibrosis Therapeutics Forecasted Market Size by Type (2025-2030)
5 Cystic Fibrosis Therapeutics Breakdown Data by Application
5.1 Global Cystic Fibrosis Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Cystic Fibrosis Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Cystic Fibrosis Therapeutics Market Size (2019-2030)
6.2 North America Cystic Fibrosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Cystic Fibrosis Therapeutics Market Size by Country (2019-2024)
6.4 North America Cystic Fibrosis Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cystic Fibrosis Therapeutics Market Size (2019-2030)
7.2 Europe Cystic Fibrosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Cystic Fibrosis Therapeutics Market Size by Country (2019-2024)
7.4 Europe Cystic Fibrosis Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cystic Fibrosis Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Cystic Fibrosis Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Cystic Fibrosis Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Cystic Fibrosis Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cystic Fibrosis Therapeutics Market Size (2019-2030)
9.2 Latin America Cystic Fibrosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Cystic Fibrosis Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Cystic Fibrosis Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cystic Fibrosis Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Cystic Fibrosis Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Cystic Fibrosis Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Cystic Fibrosis Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Detail
11.1.2 Vertex Pharmaceuticals Business Overview
11.1.3 Vertex Pharmaceuticals Cystic Fibrosis Therapeutics Introduction
11.1.4 Vertex Pharmaceuticals Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.1.5 Vertex Pharmaceuticals Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Detail
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Cystic Fibrosis Therapeutics Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Cystic Fibrosis Therapeutics Introduction
11.3.4 AbbVie Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Gilead Sciences
11.4.1 Gilead Sciences Company Detail
11.4.2 Gilead Sciences Business Overview
11.4.3 Gilead Sciences Cystic Fibrosis Therapeutics Introduction
11.4.4 Gilead Sciences Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.4.5 Gilead Sciences Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Cystic Fibrosis Therapeutics Introduction
11.5.4 Novartis Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Cystic Fibrosis Therapeutics Introduction
11.6.4 AstraZeneca Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 Bayer
11.7.1 Bayer Company Detail
11.7.2 Bayer Business Overview
11.7.3 Bayer Cystic Fibrosis Therapeutics Introduction
11.7.4 Bayer Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.7.5 Bayer Recent Development
11.8 Celtaxsys
11.8.1 Celtaxsys Company Detail
11.8.2 Celtaxsys Business Overview
11.8.3 Celtaxsys Cystic Fibrosis Therapeutics Introduction
11.8.4 Celtaxsys Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.8.5 Celtaxsys Recent Development
11.9 Pharmaxis
11.9.1 Pharmaxis Company Detail
11.9.2 Pharmaxis Business Overview
11.9.3 Pharmaxis Cystic Fibrosis Therapeutics Introduction
11.9.4 Pharmaxis Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.9.5 Pharmaxis Recent Development
11.10 ProQR Therapeutics
11.10.1 ProQR Therapeutics Company Detail
11.10.2 ProQR Therapeutics Business Overview
11.10.3 ProQR Therapeutics Cystic Fibrosis Therapeutics Introduction
11.10.4 ProQR Therapeutics Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.10.5 ProQR Therapeutics Recent Development
11.11 PTC Therapeutics
11.11.1 PTC Therapeutics Company Detail
11.11.2 PTC Therapeutics Business Overview
11.11.3 PTC Therapeutics Cystic Fibrosis Therapeutics Introduction
11.11.4 PTC Therapeutics Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.11.5 PTC Therapeutics Recent Development
11.12 Alcresta Therapeutics
11.12.1 Alcresta Therapeutics Company Detail
11.12.2 Alcresta Therapeutics Business Overview
11.12.3 Alcresta Therapeutics Cystic Fibrosis Therapeutics Introduction
11.12.4 Alcresta Therapeutics Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.12.5 Alcresta Therapeutics Recent Development
11.13 Insmed Incorporated
11.13.1 Insmed Incorporated Company Detail
11.13.2 Insmed Incorporated Business Overview
11.13.3 Insmed Incorporated Cystic Fibrosis Therapeutics Introduction
11.13.4 Insmed Incorporated Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.13.5 Insmed Incorporated Recent Development
11.14 Savara
11.14.1 Savara Company Detail
11.14.2 Savara Business Overview
11.14.3 Savara Cystic Fibrosis Therapeutics Introduction
11.14.4 Savara Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.14.5 Savara Recent Development
11.15 Cyclacel Pharmaceuticals
11.15.1 Cyclacel Pharmaceuticals Company Detail
11.15.2 Cyclacel Pharmaceuticals Business Overview
11.15.3 Cyclacel Pharmaceuticals Cystic Fibrosis Therapeutics Introduction
11.15.4 Cyclacel Pharmaceuticals Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.15.5 Cyclacel Pharmaceuticals Recent Development
11.16 Vectura
11.16.1 Vectura Company Detail
11.16.2 Vectura Business Overview
11.16.3 Vectura Cystic Fibrosis Therapeutics Introduction
11.16.4 Vectura Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.16.5 Vectura Recent Development
11.17 Allergan
11.17.1 Allergan Company Detail
11.17.2 Allergan Business Overview
11.17.3 Allergan Cystic Fibrosis Therapeutics Introduction
11.17.4 Allergan Revenue in Cystic Fibrosis Therapeutics Business (2019-2024)
11.17.5 Allergan Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
